The news: Johnson & Johnson reached a $5.5 billion settlement to resolve most of its remaining talc-related ovarian cancer lawsuits. The agreement requires participation from plaintiff firms representing at least 95% of roughly 76,000 pending claims. J&J would pay up to $3 billion in 2027, with no additional payments before 2028.

Zooming out: The company stopped selling talc-based Johnson's Baby Powder, the product at the center of the lawsuits, in the US in 2020 and globally in 2023. It continues to deny its talc products cause cancer and says the settlement is the most efficient way to end the litigation. The proposal follows years of failed efforts by J&J to resolve the litigation through a subsidiary bankruptcy strategy that courts repeatedly rejected, pushing the company toward direct settlement talks. It also builds on earlier settlements covering most talc-related mesothelioma lawsuits, state consumer protection claims, and disputes with talc suppliers.

Why it matters: J&J's stock and public reputation have largely held up through 15 years of talc litigation. Despite negative publicity, unfavorable court rulings, and criticism of its legal strategy, the company has consistently ranked among the most respected healthcare companies, thanks in part to a broad portfolio of well-regarded pharma and healthcare products, landing on Fortune's Most Admired Companies list for 24 consecutive years. J&J's stock rose 47% in 2025, and it has retained its AAA credit rating as investors largely viewed the talc litigation as a legal issue separate from its core pharmaceutical business.

Implications for pharma and healthcare marketers: The deal applies only to currently pending claims rather than future ones, so new lawsuits could still emerge as diagnoses continue or plaintiffs' firms file fresh cases. However, J&J's ability to maintain a relatively strong corporate reputation despite years of litigation suggests it is well positioned to manage the reputational impact of future legal challenges.

J&J's broad portfolio of trusted consumer brands, like Baby Shampoo and Band-Aids, gave it reputational resilience that many pharma and healthcare companies don't have today. But the broader lesson for healthcare and pharma companies is to diversify reputational strength across products and stakeholder groups. That could mean earning physician trust in one therapy area, building a strong patient community around another, and maintaining credibility with investors and policymakers. When one product comes under pressure, those other relationships can help sustain confidence in the broader company.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.